**Background:** Advanced heart failure (AHF) is a growing problem in aging populations, with symptoms refractory to optimal medical therapy. While heart transplantation remains the gold standard, donor shortage makes it unattainable for most patients. Left ventricular assist devices (LVAD) have emerged as destination therapy (DT-LVAD) for non-transplant candidates. According to the 2022 INTERMACS registry, DT-LVAD increased from 50.4% to 66.4% of all LVAD implants between 2017–2021, reaching 81.1% in 2021 alone. This narrative review covers technological evolution, prognosis, and patient selection for DT-LVAD.
**Methods:** This is a narrative review synthesizing data from pivotal randomized controlled trials (REMATCH, HeartMate II, ENDURANCE, MOMENTUM 3), large registries (INTERMACS, IMACS, MedaMACS, REGALAD), and expert consensus documents from the European Society of Cardiology and ISHLT. The review covers device generations, survival outcomes, quality of life, and a systematic evaluation of patient selection factors.
**Key Results:** LVAD technology evolved from first-generation pulsatile pumps (HeartMate VE, 52% 1-year survival in REMATCH) to second-generation axial pumps (HeartMate II, 58% 2-year survival) and third-generation centrifugal pumps with full magnetic levitation (HeartMate III). In the MOMENTUM 3 trial, HeartMate III showed significantly better event-free survival than HeartMate II (76.9% vs. 64.8% free from disabling stroke or reoperation), with 5-year follow-up confirming superiority (54% vs. 29.7%, p < 0.001). Among DT-LVAD patients specifically, 5-year event-free survival was 54.8% vs. 39.4% (p = 0.005). Current 1-year survival for DT-LVAD is approximately 80–83%, 2-year survival ~70–73%, and for the first time, 5-year MCS survival exceeded 50% (51.9%). Post-implant complications remain common: infection (40%) and bleeding (35%) have the highest incidence; stroke occurs in 14% at 6 months. Quality of life improves significantly—85% of patients became asymptomatic or minimally symptomatic at 1 year in the INTrEPID trial, and the ROADMAP study showed functional status improvement (30% vs. 12% with LVAD vs. OMT).
KEY PATIENT SELECTION FACTORS INCLUDE
(1) INTERMACS classes 2–4 are recommended for DT-LVAD (Class IIa, Level B); (2) Age has no absolute limit, but patients over 70 need careful frailty and organ function assessment; (3) Renal dysfunction: eGFR <30 mL/min/1.73m² or dialysis generally ineligible (40.6% in-hospital mortality, 61.5% 1-year mortality); (4) Liver dysfunction: MELD-XI score >17 indicates unacceptable surgical risk; (5) Right ventricular failure (RHF) prevalence 3–35% post-LVAD, with EUROMACS score best validated for prediction; (6) Frailty prevalence >20% in LVAD patients, with Fried scale ≥3/5 associated with poor prognosis; (7) Malignancy is not an absolute contraindication unless expected survival <1 year.
**Clinical Implications:** DT-LVAD is now a well-established, life-prolonging therapy for AHF patients ineligible for transplant, with survival and quality of life benefits substantially exceeding medical management. The key to optimizing outcomes lies in rigorous, multidisciplinary pre-implant evaluation. Specialized non-transplant LVAD centers can achieve comparable outcomes to transplant centers. The review emphasizes that careful assessment of renal function (including proteinuria, FENa, FEUN, and imaging), liver function (MELD-XI), right heart hemodynamics, frailty (using validated scales like Fried or Rockwood), and psychosocial factors (SIPAT) is essential. Future directions include transdermal charging systems to eliminate driveline infections, with Leviticus FiVAD already piloted in two patients as a bridge to transplant.